ImmunAbs, a leading clinical-stage biotechnology company focused on developing novel antibody therapeutics, today announced the successful completion of the Phase 1 clinical trial for IM-101. IM- 101 is a humanized monoclonal antibody that targets complement C5, which plays a central role in complement activation. The crucial role of the complement system in autoimmune diseases is well known.

The randomized, double-blind, placebo-controlled study was conducted to evaluate the safety, tolerability and preliminary efficacy of IM-101, a drug that targets the complement system, specifically complement C5. Healthy volunteers received a single dose of IM-101 or placebo. IM-101 was found to be well tolerated as no serious adverse events or dose-limiting toxicity (DLT) were observed at any of the doses tested. ImmunAbs is pleased to report that the study successfully met all predefined endpoints.

Dr. Dongjo Kim, Managing Director of ImmunAbs, expressed excitement about the results, stating: “We are pleased to announce that the topline results are positive. In this study, we examined an important biomarker of complement inhibition - the concentration of free C5 in serum - thereby confirming the effectiveness of IM-101 in binding to C5 in humans. These results provide a solid foundation to address the unmet medical needs of patients who continue to experience symptoms despite current standard treatment. We are very excited about the therapeutic potential of IM-101 in the upcoming Phase 2 study."

Information about ImmunAbs:

ImmunAbs is a clinical-stage biotechnology company founded in 2017. The Company's mission is to develop novel antibody therapeutics globally, with a particular focus on its core program to treat severe autoimmune diseases. Supported by equity capital and government grants, ImmunAbs is actively seeking further investment and collaboration with the healthcare industry to bring IM-101 to market.

Source: prnewswire.com